We Claim:

1. A method of producing an antibody or antigen-binding fragment thereof comprising:

expressing said antibody or antigen-binding fragment thereof which is engineered to contain a glycosylation site in the non-Fc constant heavy chain region, wherein said antibody or antigen-binding fragment is glycosylated in the CH1 region, or in the constant light chain region, wherein genes encoding said heavy chain and light chain regions have been engineered with a mutation such that a glycosylation site is created in the CH1 region gene or the constant light chain gene, and operably linked to expression control elements in an expression vector, in a cell that allows glycosylation; and

producing said antibody or antibody fragment glycosylated in the CH1 region or the light chain constant region in said cell.

2. The method of claim 1, wherein said expression vector comprises an amplifiable dihydrofolate reductase (dhfr) gene.

3. The method of claim 2, wherein said expression vector is pdHL2.

4. The method of claim 3, wherein said cell is a SP2/0 myeloma cell.

5. The method of claim 1, wherein the antibody or fragment thereof comprises a humanized antibody or antigen-binding fragment thereof.

6. The method of claim 1, wherein the antibody or fragment thereof comprises a humanized B-cell specific antibody or antigen-binding fragment thereof.

7. The method of claim 6, wherein said glycosylation is located on a site selected from the group consisting of the HCN1, HCN2, HCN3, HCN4, and HCN5 sites (SEQ ID NOS: 10-14) of Figure 12.

8. The method of claim 7, wherein said glycosylation site is the HCN5 site (SEQ ID NO: 10) of Figure 12.

9. The method of claim 7, wherein said glycosylation site is the HCN1 site (SEQ ID NO: 10) of Figure 12.

10. The method of claim 6, wherein the antibody or antigen-binding fragment thereof is engineered to contain a glycosylation site is an antibody or antigen-binding fragment thereof having the binding specificity of the hLL2 antibody.

11. The method of claim 1, wherein said glycosylation is located at a N-linked glycosylation site.

12. The method of claim 10, wherein said expression vector comprises an amplifiable dihydrofolate reductase (dhfr) gene.

13. The method of claim 12, wherein said expression vector is pdHL2.

14. The method of claim 13, wherein said cell is a SP2/0 myeloma cell.

15. The method of claim 1, wherein said antibody or fragment thereof is encoded by a DNA molecule comprising a DNA sequence comprising an engineered glycosylation site in the DNA sequence encoding the CH1 region or the constant light chain region.